Systemic Lupus Erythematosus or SLE is an autoimmune disease in which the immune system attacks its own tissues, causing chronic inflammation and tissue damage in the affected organs across the body, including joints, skin, brain, lungs, kidneys and blood vessels. Although SLE can affect people of all ages, it typically strikes females at far greater rates than males, particularly in younger age groups. Among other medications, oral corticosteroids are main therapeutic agents predominantly used to control systemic inflammations. Nevertheless, these drugs pose some undesired effects including early hip osteoarthritis.
Systemic Lupus Erythematosus or SLE is an autoimmune disease occurs when the body’s immune system attacks its own tissues and organs. Since the inflammation is systematic, SLE can affect different systems in the body, including joints, skin, kidneys, blood cells, brain, heart and lungs. Clinical manifestations widely vary among individuals which may come on suddenly or develop gradually. Most common signs and symptoms of SLE are fever, fatigue, butterfly-shaped rash, loss of appetite, headache and joint or muscle pain accompanied by stiffness and swelling. If the inflammation caused by SLE involves the musculoskeletal system, the most affected parts are wrist, finger, ankle, knee and hip.
Depending signs and symptoms, the medications often used to control inflammation include non-steroidal anti-inflammatory drugs (NSAIDs), immunosuppressants and corticosteroids.
Regardless of doses, long-term use corticosteroids can substantially increase the risk of avascular necrosis (or osteonecrosis) of the hip which is the death of bone tissue due to a lack or disruption of blood supply to the head of femur. Therefore, SLE does not seem to be the causative factor of hip osteonecrosis directly, instead, long-term use of steroid drugs as a main therapy of SLE can potentially induce hip osteonecrosis. Nevertheless, the risk of developing hip osteoarthritis hinges upon overall health status of each individual.
Hip osteonecrosis induced by SLE can be classified into 4 stages, based on severity levels and impacts on daily life:
Once hip osteonecrosis develops, it cannot be reversed. Treatments are aimed to reduce pain and improve mobility while preserving patient’s quality of life. Treatment options of hip osteonecrosis induced by SLE are primarily determined by symptoms severity. Treatments include:
Corticosteroids are a type of anti-inflammatory drug. They are typically prescribed to treat a wide range of conditions, such as SLE, sudden sensorineural hearing loss, asthma, neuromyelitis optica spectrum disorder, glomerulonephritis and other inflammatory diseases. The appropriate dosage regimens for each condition are determined by the specialists. Corticosteroids do not tend to cause significant side effects if they are only taken for a short time or at a low dose. However, they might induce hip osteonecrosis in which its occurrence appears to be irrelevant to administered dose and duration, but individual’s response and overall health status.